PPV23 vaccine is effective against pneumococcal disease in the elderly

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • The 23-valent pnsumococcal polysaccharide vaccine (PPV23; Prevnar) is effective against invasive pneumococcal disease (IPD) and pneumoccal pneumonia in the elderly, according to a meta-analysis.
Why this matters
  • High rates of hospitalizations and mortality are observed in the 20-30% of cases of community-acquired pneumonia caused by pneumococcus.
Study design
  • 17 clinical trials, cohort studies and case-control studies met eligibility criteria after search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews.
  • Risk of bias was assessed.
  • Random effects meta-analysis was conducted.
  • Funding: No external funding was used.
Key results
  • For IPD, the pooled vaccine effectiveness (VE) in adults ≥60 y was 73% (95% CI, 10%-92%) in 4 clinical trials, 45% (95% CI, 15%-65%) in 3 cohort studies, and 59% (95% CI, 35%-74%) in 3 case-control studies.
  • For pneumococcal pneumonia, the pooled VE in adults ≥60 y was 64% (95% CI, 35%-80%) in 2 clinical trials and 48% (95% CI, 25%-63%) in 2 cohort studies.
Limitations
  • Few clinical trials met eligibility criteria.